M&A Deal Summary

Ipsen Acquires Merrimack Pharmaceuticals - Oncology Assets

On January 8, 2017, Ipsen acquired life science company Merrimack Pharmaceuticals - Oncology Assets from Merrimack Pharmaceuticals for 575M USD

Acquisition Highlights
  • This is Ipsen’s 6th transaction in the Life Science sector.
  • This is Ipsen’s 2nd largest (disclosed) transaction.
  • This is Ipsen’s 3rd transaction in the United States.
  • This is Ipsen’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2017-01-08
Target Merrimack Pharmaceuticals - Oncology Assets
Sector Life Science
Buyer(s) Ipsen
Sellers(s) Merrimack Pharmaceuticals
Deal Type Divestiture
Deal Value 575M USD

Target

Merrimack Pharmaceuticals - Oncology Assets

Cambridge, Massachusetts, United States
Merrimack Pharmaceuticals, Inc. - Oncology Assets is a unique encapsulation formulation of irinotecan in a long-circulating liposomal form designed to increase the length of tumor exposure to irinotecan and its active metabolite SN-38.

Search 193,605 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ipsen

Boulogne-Billancourt, France

website

Category Company
Founded 1929
Sector Life Science
Employees5,072
Revenue 3.2B EUR (2022)
DESCRIPTION

Ipsen is a research and development pharmaceutical comapany. It manufactures specialty pharmaceuticals and has a worldwide sales presence. Ipsen focuses on products in the gastro-enterology, neurology and cardiovascular therapeutic areas and has also developed specific expertise in some biotech niches such as endocrinology, oncology, neurology and hematology. Ipsen was founded in 1929 and is based in Boulogne-Billancourt, France.

DEAL STATS #
Overall 6 of 11
Sector (Life Science) 6 of 11
Type (Divestiture) 1 of 2
State (Massachusetts) 1 of 3
Country (United States) 3 of 5
Year (2017) 1 of 3
Size (of disclosed) 2 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-02-24 Canbex Therapeutics

London, United Kingdom

Canbex Therapeutics Ltd. develop its proprietary VSN compound series in spasticity and other unmet medical needs.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-31 Akkadeas Pharma Srl

Milano, Italy

Akkadeas Pharma Srl is a privately-held consumer health care company in Italy with a diversified gastrointestinal-focused portfolio including probiotics, medical devices and food supplements.

Buy -

Seller(S) 1

SELLER

Merrimack Pharmaceuticals

Cambridge, Massachusetts, United States

website

Category Company
Founded 1993
Sector Life Science
DESCRIPTION

Merrimack Pharmaceuticals, Inc. is a bio-pharmaceutical company develops commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-12-07 HERMES Biosciences

South San Francisco, California, United States

HERMES Biosciences, Inc. develops targeted drug delivery technologies for therapeutic and other biomedical applications.

Buy -
Mergr

Product

Company

Legal